CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback